Recent inspection trends reinforce a fundamental principle: organisations cannot control risks that they cannot see. Data integrity failures, supply chain vulnerabilities, and system fragmentation all point to the same underlying issue—insufficient visibility into the true state of operations.
Mastering data integrity and Good Documentation Practice is essential for maintaining regulatory compliance and ensuring scientific validity in therapeutic goods development and manufacturing. These principles form the backbone of trustworthy data systems and are essential for demonstrating control, traceability, and reproducibility.
By implementing structured, risk-based, and auditable recordkeeping practices, therapeutic goods manufacturers, testing laboratories, and biotechnology companies can confidently demonstrate that their data management systems are not just “adequate,” but robust, compliant, and ready for inspection and growth.